アセタゾラミド (Synonyms: Acetazolamide)

Name: Acetazolamide
Brand: MedChemExpress
SKU: HY-B0782
Rating: 5.0 (13 reviews)

製品番号: HY-B0782 純度: 99.85%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC₅₀ of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 59-66-5

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	在庫あり	Estimated Time of Arrival: December 31
Solid
500 mg	$50	在庫あり	Estimated Time of Arrival: December 31
1 g	$60	在庫あり	Estimated Time of Arrival: December 31
5 g	$96	在庫あり	Estimated Time of Arrival: December 31
10 g		お問い合わせ
50 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 13 publication(s) in Google Scholar

Other Forms of Acetazolamide:

Acetazolamide-d₃ 在庫あり
Acetazolamide sodium 在庫あり
Acetazolamide (Standard) 在庫あり
Acetazolamide-¹³C₂,d₃ お問い合わせ
Acetazolamide-¹⁵N,d₃ お問い合わせ

顧客検証

Bio/Physico-chemical Assay

: Acetazolamide purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Apr 17;13(4):473.; Effect of Acetazolamide, a CA inhibitor, on oxidation of PTEN by H₂O₂. HepG2 cells were pre-incubated in HCO₃⁻-free media, supplemented with 0, 0.01, 0.1, 1, and 10 µM Acetazolamide, at 37 °C with 0.1% CO₂ for 4 h. Then, they were changed to stimulation media with same components plus 0.5 mM H₂O₂. After 10 min, the reaction was terminated by NEM-containing lysis buffer. Western blot data with PTEN and β-actin antibodies are shown Acetazolamide considerably impeded PTEN oxidation in a dose-dependent manner.

: Acetazolamide purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Apr 17;13(4):473.; Effect of Acetazolamide, a CA inhibitor, on oxidation of PTEN by H₂O₂. HepG2 cells were pre-incubated in HCO₃⁻-free media, supplemented with 0, 0.01, 0.1, 1, and 10 µM Acetazolamide, at 37 °C with 0.1% CO₂ for 4 h. Then, they were changed to stimulation media with same components plus 0.5 mM H₂O₂. After 10 min, the reaction was terminated by NEM-containing lysis buffer. Western blot data with PTEN and β-actin antibodies are shown. Stars are considered as significances.

: Acetazolamide purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 May 17;42(5):112529. [Abstract]; GSIS was measured via static incubation in male human islets (n = 3–7 donors, 10 IEQ/condition measured in triplicate) cultured for 24 h with vehicle or DHT (10 nM) and then for 40 min in the presence or absence of a carbonic anhydrase inhibitor Acetazolamide (50 μM).

: Acetazolamide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Feb 2;7:e33432. [Abstract]; Intracellular pH (pHi) of the ligated efferent ductules with or without Acetazolamide(500 μM) from WT mice and Adgrg2^-/Y mice.

Carbonic Anhydrase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

CA CA I CA Ⅱ CA IX CA XII CA VII CA VI CA VA CA VB CA XIII CA XIV

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC₅₀ of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities^[1]^[4]^[5]^[6].

IC₅₀ & Target

CA IX

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	2.83 3 Compound: AZA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay	[PMID: 31901743]
HeLa	IC₅₀	2.83 3 Compound: AZA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay	[PMID: 31901743]
HeLa	IC₅₀	7.82 3 Compound: AZA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay	[PMID: 31901743]
HeLa	IC₅₀	7.82 3 Compound: AZA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay	[PMID: 31901743]
HT-29	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	>100 3 Compound: AAZ	Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	53.78 3 Compound: AAZ	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay	[PMID: 31542715]
HT-29	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	53.78 3 Compound: AAZ	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay	[PMID: 31542715]
MDA-MB-231	IC₅₀	>100 3 Compound: AAZ	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
Oocyte	IC₅₀	0.9 3 Compound: 1	Inhibition of human AQP4b-mediated water transport in Xenopus oocytes Inhibition of human AQP4b-mediated water transport in Xenopus oocytes	[PMID: 17178220]
MDA-MB-231	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
Oocyte	IC₅₀	0.86 3 Compound: 1	Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes	[PMID: 18178093]
MDA-MB-231	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
WI-38	IC₅₀	14.45 3 Compound: AZA	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31901743]
WI-38	IC₅₀	14.45 3 Compound: AZA	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31901743]
HT-29	IC₅₀	53.78 3 Compound: AAZ	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay	[PMID: 31542715]
HT-29	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
HeLa	IC₅₀	2.83 3 Compound: AZA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay	[PMID: 31901743]
HeLa	IC₅₀	7.82 3 Compound: AZA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay	[PMID: 31901743]
MDA-MB-231	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
MDA-MB-231	IC₅₀	> 100 3 Compound: AAZ	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
Oocyte	IC₅₀	0.86 3 Compound: 1	Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes	[PMID: 18178093]
Oocyte	IC₅₀	0.9 3 Compound: 1	Inhibition of human AQP4b-mediated water transport in Xenopus oocytes Inhibition of human AQP4b-mediated water transport in Xenopus oocytes	[PMID: 17178220]
WI-38	IC₅₀	14.45 3 Compound: AZA	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31901743]

体外実験

Acetazolamide also inhibits hCA II with an IC₅₀ of 130 nM^[1].
Acetazolamide (Ace) is a small heteroaromatic sulfonamide that binds to various carbonic anhydrases with high affinity, acting as a carbonic anhydrase (CA) inhibitor^[2].
Compared with the control group, the high Acetazolamide concentration (AceH, 50 nM), Cisplatin (Cis; 1 μg/mL) and Cis combined with the low Acetazolamide concentration (AceL, 10 nM) treatments significantly reduces viability of Hep-2 cells^[2].
Treatment with the Acetazolamide/Cis combination significantly increases the expression levels of P53, as both AceL+Cis and AceH+Cis treatments result in significantly increased P53 protein expression levels compared with the control group. The Ace/Cis combination treatment significantly reduces the bcl-2/bax expression ratio, and increases the expression of caspase-3 protein, compared with the control group. AceL, AceH, Cis and AceL+Cis treatments significantly reduce the bcl-2/bax ratio compared with the control group^[2].
Combined Ace and Cis treatment effectively promotes apoptosis in Hep-2 cells^[2].
Combined treatment with Ace/Cis markedly decreases the expression of AQP1 mRNA in Hep-2 cells. Both AceH and AceL+Cis treatments decrease the expression of aquaporin-1 (AQP1) mRNA in Hep-2 cells compared with the control group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Acetazolamide (40 mg/kg) significantly potentiates the inhibitory effect of MS-275 on tumorigenesis in neuroblastoma (NB) SH-SY5Y xenografts^[3].
Acetazolamide (40 mg/kg) and/or MS-275 treatment reduce expression of HIF1-α and CAIX in NB SH-SY5Y xenograft^[3].
Acetazolamide (40 mg/kg), MS-275 and Acetazolamide+MS-275 reduce expression of mitotic and proliferative markers in NB SH-SY5Y xenografts^[3].
Acetazolamide (50 mg/kg; PO, for 3 days) significantly reduces the gonococcal load in the vagina of infected mice by 90%^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

222.25

分子式

C₄H₆N₄O₃S₂

CAS 番号

59-66-5

Appearance

Solid

Color

White to off-white

SMILES

CC(NC1=NN=C(S(=O)(N)=O)S1)=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (224.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.4994 mL	22.4972 mL	44.9944 mL
5 mM	0.8999 mL	4.4994 mL	8.9989 mL
10 mM	0.4499 mL	2.2497 mL	4.4994 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (11.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 1.96 mg/mL (8.82 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.85%

Select Batch:

データシート (281 KB) SDS (393 KB)

COA (249 KB) HNMR (233 KB) RP-HPLC (247 KB) MS (229 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Hou Z, et al. Dual-tail approach to discovery of novel carbonic anhydrase IX inhibitors by simultaneously matching the hydrophobic and hydrophilic halves of the active site. Eur J Med Chem. 2017 May 26;132:1-10. [Content Brief]

[2]. Bayat Mokhtari R, et al. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer. 2017 Feb 24;17(1):156. [Content Brief]

[3]. Gao H, et al. Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. Oncol Lett. 2018 Jun;15(6):9299-9306. [Content Brief]

[4]. Kassamali R, et al. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011 Nov-Dec;19(6):276-8. [Content Brief]

[5]. Jabeen E, et al. Interaction of antihypertensive acetazolamide with nonsteroidal anti-inflammatory drugs. J Photochem Photobiol B. 2013 Aug 5;125:155-63. [Content Brief]

[6]. Abutaleb NS, et al. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microb Pathog. 2022 Mar;164:105454. [Content Brief]

細胞実験	Cell Viability Assay^[2] Cell line: Hep-2 cells and HUVECs Concentration: 10 nM and 50 nM Incubation time: 48 h Assay: The cell viability of Hep-2 cells and HUVECs is measured by MTT assay. Hep-2 cells and HUVECs in logarithmic growth phase are plated in 96-well plates. Following 48 h of drug treatment as indicated, 200 µL MTT (5 mg/mL) is added to each well. Cells are incubated with the MTT solution at 37°C for 4 h. Then, 150 µL DMSO is added for 5 min. The optical density (OD) values are measured at 490 nm with a Versamax Microplate reader. Note: Combined treatment effectively reduced viability in Hep-2 cells. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験	In vivo studies^[3] Animal model: 4-6 weeks-old female NOD/SCID mice Dosage: 40 mg/kg, intraperitoneal injection, every day for 2 weeks Administration: Mice are randomized into four groups (5 mice per group). The control and treatment groups receive intraperitoneal injections of vehicle (PBS) or Acetazolamide (40 mg/kg), MS-275 (20 mg/kg) or the combination, respectively, every day for 2 weeks. Experiments are terminated when tumor sizes exceed 2 cm3 in volume or animals show signs of morbidity. Tumor diameters are measured on a daily basis until termination. Note: Inhibited tumor growth of NB xenografts with significant anti-tumor growth potentiation effect. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Hou Z, et al. Dual-tail approach to discovery of novel carbonic anhydrase IX inhibitors by simultaneously matching the hydrophobic and hydrophilic halves of the active site. Eur J Med Chem. 2017 May 26;132:1-10. [Content Brief] [2]. Bayat Mokhtari R, et al. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer. 2017 Feb 24;17(1):156. [Content Brief] [3]. Gao H, et al. Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. Oncol Lett. 2018 Jun;15(6):9299-9306. [Content Brief] [4]. Kassamali R, et al. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011 Nov-Dec;19(6):276-8. [Content Brief] [5]. Jabeen E, et al. Interaction of antihypertensive acetazolamide with nonsteroidal anti-inflammatory drugs. J Photochem Photobiol B. 2013 Aug 5;125:155-63. [Content Brief] [6]. Abutaleb NS, et al. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microb Pathog. 2022 Mar;164:105454. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.4994 mL	22.4972 mL	44.9944 mL	112.4859 mL
	5 mM	0.8999 mL	4.4994 mL	8.9989 mL	22.4972 mL
	10 mM	0.4499 mL	2.2497 mL	4.4994 mL	11.2486 mL
	15 mM	0.3000 mL	1.4998 mL	2.9996 mL	7.4991 mL
	20 mM	0.2250 mL	1.1249 mL	2.2497 mL	5.6243 mL
	25 mM	0.1800 mL	0.8999 mL	1.7998 mL	4.4994 mL
	30 mM	0.1500 mL	0.7499 mL	1.4998 mL	3.7495 mL
	40 mM	0.1125 mL	0.5624 mL	1.1249 mL	2.8121 mL
	50 mM	0.0900 mL	0.4499 mL	0.8999 mL	2.2497 mL
	60 mM	0.0750 mL	0.3750 mL	0.7499 mL	1.8748 mL
	80 mM	0.0562 mL	0.2812 mL	0.5624 mL	1.4061 mL
	100 mM	0.0450 mL	0.2250 mL	0.4499 mL	1.1249 mL

Acetazolamide Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Acetazolamide59-66-5Carbonic AnhydraseAutophagyBacterialCarbonate dehydratasediureticantihypertensiveanti-gonococcalNeisseria gonorrhoeaeInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

アセタゾラミド (Synonyms: Acetazolamide)

カスタマーレビュー

Other Forms of Acetazolamide:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Carbonic Anhydrase アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Acetazolamide Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

アセタゾラミド (Synonyms: Acetazolamide)

カスタマーレビュー

Other Forms of Acetazolamide:

アセタゾラミド 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Carbonic Anhydrase アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

アセタゾラミド 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Acetazolamide Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

アセタゾラミド関連抗体

アセタゾラミド関連抗体